Smartleaf Asset Management LLC Raises Stake in Amgen Inc. $AMGN

Smartleaf Asset Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 36.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,861 shares of the medical research company’s stock after purchasing an additional 1,831 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Amgen were worth $1,880,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Legacy Investment Solutions LLC purchased a new stake in Amgen during the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP bought a new stake in shares of Amgen during the second quarter valued at approximately $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen during the second quarter valued at approximately $32,000. Quaker Wealth Management LLC boosted its stake in Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the last quarter. Finally, Cloud Capital Management LLC purchased a new position in shares of Amgen in the third quarter worth $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $384.20 on Monday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a 50-day simple moving average of $334.45 and a two-hundred day simple moving average of $311.51. The firm has a market capitalization of $206.88 billion, a PE ratio of 27.00, a P/E/G ratio of 3.96 and a beta of 0.46. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s dividend payout ratio is 66.90%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AMGN shares. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. HSBC restated a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Leerink Partners boosted their target price on shares of Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday. Finally, DZ Bank lifted their price objective on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $351.65.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.